A near 35-percent market correction over the last couple of weeks has provided an opportunity to buy good blue-chip and quality names at reasonable valuations, Mahesh Patil, Co-Chief Investment Officer, Aditya Birla Sun Life AMC told CNBC-TV18 in an interview. However, he pointed out that we may not have seen the bottom in the market yet.
The coronavirus outbreak, he said, will cause significant growth slowdown over the next few quarters with a lot of sectors getting impacted.
"It will have an impact across sectors whether it is consumption, whether it is the services sector, infrastructure and to that extent one would have to look at companies or sectors, which would get impacted temporarily and which would be able to bounce back once things normalize," he said, adding that there could be some medium-term impact in a few sectors because the recovery from the current slowdown would be slow and gradual.
Follow LIVE updates on the COVID-19 outbreak here
"There is some rejig in the portfolio, which we are doing at this point in time,” he said. “Stocks, which we earlier wanted to buy but were very expensive are now coming in at price points which are comfortable from our perspective and we are trying to rejig the portfolio in some of these names and overall trying to keep some liquidity in the portfolio because I don’t think we have seen the bottom in the market but the market will provide opportunities where it will probably again retest the earlier lows,” said Patil in an interview with CNBC-TV18.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
In terms of investor behavior, he further mentioned, “Interestingly, in this month of March, we have seen that inflows have been good compared to the last few months, you will see record flows in this month, that is what the initial indication is. Investors are acting in a much more matured way. They are seeing that the market correction is offering a good opportunity to make some larger equity allocation because over a medium to long-term one should make good returns from these levels.”
“Although there have been some redemptions, overall on a net basis, it is a fairly decent inflow. The market remains weak for the same period of time than the initial bout of money which has come in, that might slow down and the next month will be crucial to see how the market stabilizes,” he said.